BeOne Medicines (BEIGF) Cash from Financing Activities (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Cash from Financing Activities data on file, last reported at $68.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $68.6 million, up 303.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 44428.88% YoY), and the FY2025 annual result was $1.1 billion, up 447.66% from the prior year.
• Cash from Financing Activities slipped to $68.6 million in Q1 2026 per BEIGF's latest filing, from $96.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $961.3 million in Q3 2025 and troughed at -$110.4 million in Q4 2022.
• A 5-year average of $101.1 million and a median of $23.0 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities tumbled 163.86% in 2023, then surged 7491.79% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at -$110.4 million in 2022, then surged by 414.45% to $347.0 million in 2023, then slumped by 101.3% to -$4.5 million in 2024, then soared by 2243.07% to $96.9 million in 2025, then slipped by 29.19% to $68.6 million in 2026.
• Business Quant data shows BEIGF's Cash from Financing Activities at $68.6 million in Q1 2026, $96.9 million in Q4 2025, and $961.3 million in Q3 2025.